191 related articles for article (PubMed ID: 37729870)
21. Biomarkers for pancreatic cancer based on tissue and serum metabolomics analysis in a multicenter study.
Zhao R; Ren S; Li C; Guo K; Lu Z; Tian L; He J; Zhang K; Cao Y; Liu S; Li D; Wang Z
Cancer Med; 2023 Feb; 12(4):5158-5171. PubMed ID: 36161527
[TBL] [Abstract][Full Text] [Related]
22. Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer.
Takano S; Sogawa K; Yoshitomi H; Shida T; Mogushi K; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Ishihara T; Tanaka H; Yokosuka O; Nomura F; Miyazaki M
Br J Cancer; 2010 Jul; 103(2):223-31. PubMed ID: 20551957
[TBL] [Abstract][Full Text] [Related]
23. Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.
Fahrmann JF; Marsh T; Irajizad E; Patel N; Murage E; Vykoukal J; Dennison JB; Do KA; Ostrin E; Spitz MR; Lam S; Shete S; Meza R; Tammemägi MC; Feng Z; Hanash SM
J Clin Oncol; 2022 Mar; 40(8):876-883. PubMed ID: 34995129
[TBL] [Abstract][Full Text] [Related]
24. An Integrative Pancreatic Cancer Risk Prediction Model in the UK Biobank.
Ke TM; Lophatananon A; Muir KR
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137427
[TBL] [Abstract][Full Text] [Related]
25. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
26. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer.
Ben-Ami R; Wang QL; Zhang J; Supplee JG; Fahrmann JF; Lehmann-Werman R; Brais LK; Nowak J; Yuan C; Loftus M; Babic A; Irajizad E; Davidi T; Zick A; Hubert A; Neiman D; Piyanzin S; Gal-Rosenberg O; Horn A; Shemer R; Glaser B; Boos N; Jajoo K; Lee L; Clancy TE; Rubinson DA; Ng K; Chabot JA; Kastrinos F; Kluger M; Aguirre AJ; Jänne PA; Bardeesy N; Stanger B; O'Hara MH; Till J; Maitra A; Carpenter EL; Bullock AJ; Genkinger J; Hanash SM; Paweletz CP; Dor Y; Wolpin BM
Gut; 2024 Mar; 73(4):639-648. PubMed ID: 38123998
[TBL] [Abstract][Full Text] [Related]
27. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
[TBL] [Abstract][Full Text] [Related]
28. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.
Liu L; Xu H; Wang W; Wu C; Chen Y; Yang J; Cen P; Xu J; Liu C; Long J; Guha S; Fu D; Ni Q; Jatoi A; Chari S; McCleary-Wheeler AL; Fernandez-Zapico ME; Li M; Yu X
Int J Cancer; 2015 May; 136(9):2216-27. PubMed ID: 25273947
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9.
Forsmark CE; Lambiase L; Vogel SB
Pancreas; 1994 Nov; 9(6):731-4. PubMed ID: 7846016
[TBL] [Abstract][Full Text] [Related]
30. Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort.
Irajizad E; Fahrmann JF; Marsh T; Vykoukal J; Dennison JB; Long JP; Do KA; Feng Z; Hanash S; Ostrin EJ
J Clin Oncol; 2023 Sep; 41(27):4360-4368. PubMed ID: 37379494
[TBL] [Abstract][Full Text] [Related]
31. A Novel and Robust Long Noncoding RNA Panel to Predict the Prognosis of Pancreatic Cancer.
Li M; Li H; Chen Q; Wu W; Chen X; Ran L; Si G; Tan X
DNA Cell Biol; 2020 Jul; 39(7):1282-1289. PubMed ID: 32522048
[TBL] [Abstract][Full Text] [Related]
32. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
[TBL] [Abstract][Full Text] [Related]
33. Exploration of the value of MRCP combined with tumor marker CA19-9 in the diagnosis of pancreatic cancer.
Ma S; Duan J; Li W; Zhang H; Hou Z
Artif Cells Nanomed Biotechnol; 2016; 44(2):717-21. PubMed ID: 25472755
[TBL] [Abstract][Full Text] [Related]
34. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.
Abe T; Koi C; Kohi S; Song KB; Tamura K; Macgregor-Das A; Kitaoka N; Chuidian M; Ford M; Dbouk M; Borges M; He J; Burkhart R; Wolfgang CL; Klein AP; Eshleman JR; Hruban RH; Canto MI; Goggins M
Clin Gastroenterol Hepatol; 2020 May; 18(5):1161-1169.e5. PubMed ID: 31676359
[TBL] [Abstract][Full Text] [Related]
35. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
37. A Blood-Based Metabolite Panel for Distinguishing Ovarian Cancer from Benign Pelvic Masses.
Irajizad E; Han CY; Celestino J; Wu R; Murage E; Spencer R; Dennison JB; Vykoukal J; Long JP; Do KA; Drescher C; Lu K; Lu Z; Bast RC; Hanash S; Fahrmann JF
Clin Cancer Res; 2022 Nov; 28(21):4669-4676. PubMed ID: 36037307
[TBL] [Abstract][Full Text] [Related]
38. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
Parikh DA; Durbin-Johnson B; Urayama S
J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
[TBL] [Abstract][Full Text] [Related]
39. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.
Kuwatani M; Kawakami H; Kubota Y; Kawakubo K; Ito YM; Togo S; Ikeda T; Kusama K; Kobayashi Y; Murata T; Sakamoto N
Pancreatology; 2019 Jun; 19(4):569-577. PubMed ID: 31031206
[TBL] [Abstract][Full Text] [Related]
40. A quantitative multimodal metabolomic assay for colorectal cancer.
Farshidfar F; Kopciuk KA; Hilsden R; McGregor SE; Mazurak VC; Buie WD; MacLean A; Vogel HJ; Bathe OF
BMC Cancer; 2018 Jan; 18(1):26. PubMed ID: 29301511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
